- Home
- ALAR vs VYNE Comparison
ALAR vs VYNE Comparison
Compare ALAR & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- VYNE
- Stock Information
- Founded
- ALAR 2013
- VYNE 2003
- Country
- ALAR Israel
- VYNE United States
- Employees
- ALAR N/A
- VYNE N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- VYNE Health Care
- Exchange
- ALAR Nasdaq
- VYNE Nasdaq
- Market Cap
- ALAR 41.3M
- VYNE 35.7M
- IPO Year
- ALAR 2018
- VYNE 2018
- Fundamental
- Price
- ALAR $8.23
- VYNE $1.85
- Analyst Decision
- ALAR Strong Buy
- VYNE Strong Buy
- Analyst Count
- ALAR 1
- VYNE 2
- Target Price
- ALAR $11.00
- VYNE $6.88
- AVG Volume (30 Days)
- ALAR 112.5K
- VYNE 224.4K
- Earning Date
- ALAR 05-20-2025
- VYNE 05-08-2025
- Dividend Yield
- ALAR N/A
- VYNE N/A
- EPS Growth
- ALAR N/A
- VYNE N/A
- EPS
- ALAR 0.08
- VYNE N/A
- Revenue
- ALAR $31,824,000.00
- VYNE $501,000.00
- Revenue This Year
- ALAR $12.46
- VYNE N/A
- Revenue Next Year
- ALAR $26.00
- VYNE N/A
- P/E Ratio
- ALAR $10.03
- VYNE N/A
- Revenue Growth
- ALAR 20.00
- VYNE 18.16
- 52 Week Low
- ALAR $5.45
- VYNE $1.44
- 52 Week High
- ALAR $46.69
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- ALAR 62.86
- VYNE 53.21
- Support Level
- ALAR $5.45
- VYNE $1.76
- Resistance Level
- ALAR $7.34
- VYNE $1.93
- Average True Range (ATR)
- ALAR 0.62
- VYNE 0.16
- MACD
- ALAR 0.25
- VYNE 0.06
- Stochastic Oscillator
- ALAR 97.54
- VYNE 83.67
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.